TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae.
TEM-71, a novel extended-spectrum beta-lactamase from a Klebsiella pneumoniae clinical isolate, had an isoelectric point of 6.0 and a substrate profile showing preferential hydrolysis of cefotaxime over ceftazidime. It differed from TEM-1 by two substitutions, Gly238Ser and Glu240Lys, and was under the control of the strong P4 promoter.
Rasheed
J Kamile
JK
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. Jkr1@cdc.gov
Anderson
Gregory J
GJ
Queenan
Anne Marie
AM
Biddle
James W
JW
Oliver
Antonio
A
Jacoby
George A
GA
Bush
Karen
K
Tenover
Fred C
FC
D019943:Amino Acid Substitution; D002439:Cefotaxime / Q000378:metabolism; D002442:Ceftazidime / Q000378:metabolism; D018550:Cephalosporin Resistance / Q000235:genetics*; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology; D004269:DNA, Bacterial / Q000235:genetics; D007525:Isoelectric Focusing; D007700:Kinetics; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics*; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D010957:Plasmids / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013379:Substrate Specificity; D001618:beta-Lactamases / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
D002511:Cephalosporins; D004269:DNA, Bacterial; D002442:Ceftazidime; C466678:TEM-71 beta-lactamase; D001618:beta-Lactamases; D002439:Cefotaxime